Breaking news, AGI updates, and analysis of the intelligence revolution.
📰 News A marketing graduate in Kuala Lumpur has applied for 300 jobs in two months. In Manila, the BPO industry that gave 850,000 graduates their first job a year is automating. The first rung of Southeast Asia's career ladder is cracking.
📰 News The Krafton-backed robotics spin-out says its Ludi 0.2 system brings social intelligence, memory and gesture reading to robots built for human spaces.
📰 News The retailer's new $6 billion commitment stacks onto a decade-old robotics partnership that already runs a large share of its US distribution network.
📰 News Adoption has stopped being a memo and become a negotiation — with a scar discount, a consent veto, and a wage premium that has already crossed industry lines.
📰 News The redemption deadline passed with the trust intact: $164M from the SPAC, a $201M Foxconn-led PIPE at $10, $100M already banked — and a shareholder vote Monday.
📰 News The proclamation treats the factory floor as a security perimeter: most industrial robots sold in America are made abroad, the administration's own filing admits it, and the tariff decision is deferred to April.
📰 News Japan's whole-of-government AI platform produced its first hard numbers: satisfaction above 70%, real time savings — and a usage split that exposes how the benefits of public-sector AI pool behind skill walls.
📰 News The AI-agent detection market just moved from fingerprint-spotting to behaviour-reading. Its benchmarks are self-reported — but the problem it names is real and now has a market around it.
📰 News The strongest robot-order quarter of 2026 was powered by car parts suppliers and chip factories, with cobots up 56%.
📰 News AGIBOT's new Worken metric prices robots in useful work delivered, not units shipped. It also has obvious self-grading problems.
📰 News Banks pay 13 percent over tech for software engineers, hospitals 17 percent, and 32 percent of AI-attributed cuts get reversed. The question has moved from whether AI takes the job to who pays the most to have it done.
📰 News A one-person biotech run on Claude contracts, logistics and lab experiments is now part of Anthropic — with a muscular dystrophy candidate that doubled treated mice's grip strength in early tests. Human trials are targeted for late 2028, if the science holds.